Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab + Cetuximab + Platinum for Hypopharyngeal Cancer
NCT06151743Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Pathological Complete Response Rate. Started Jan 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT06151743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151743.